HorvathKDJobeBAHerronDMSwanstromLL. Laparoscopic Toupet fundoplication is an inadequate procedure for patients with severe reflux disease. J Gastrointest Surg. 1999;3(6):583-591.
2.
WarrenHFBrownLMMihuraMFarivarASAyeRWLouieBE. Factors influencing the outcome of magnetic sphincter augmentation for chronic gastroesophageal reflux disease. Surg Endosc. 2018;32(1):405-412.
3.
LordRVDeMeesterSRPetersJH, et al. Hiatal hernia, lower esophageal sphincter incompetence, and effectiveness of Nissen fundoplication in the spectrum of gastroesophageal reflux disease. J Gastrointest Surg. 2009;13:602-610.
4.
HofstetterWLPetersJHDeMeesterTR, et al. Long-term outcome of antireflux surgery in patients with Barrett’s esophagus. Ann Surg. 2001;234(4):532-538; discussion 538-539.
5.
KnightBCDevittPGWatsonDISmithLTJamiesonGGThompsonSK. Long-term efficacy of laparoscopic antireflux surgery on regression of Barrett’s esophagus using BRAVO wireless pH monitoring: a prospective clinical cohort study. Ann Surg. 2017;266(6):1000-1005.
6.
ShimizuDVallböhmerDKuramochiH, et al. Increasing cyclooxygenase-2 (cox-2) gene expression in the progression of Barrett’s esophagus to adenocarcinoma correlates with that of Bcl-2. Int J Cancer. 2006;119(4):765-770.
7.
VallbohmerDDeMeesterSRPetersJH, et al. Cdx-2 expression in squamous and metaplastic columnar epithelia of the esophagus. Dis Esophagus. 2006;19(4):260-266.
8.
VallbohmerDDeMeesterSROhDS, et al. Antireflux surgery normalizes cyclooxygenase-2 expression in squamous epithelium of the distal esophagus. Am J Gastroenterol. 2006;101(7):1458-1466.
9.
OhDSDeMeesterSRVallbohmerD, et al. Reduction of interleukin 8 gene expression in reflux esophagitis and Barrett’s esophagus with antireflux surgery. Arch Surg. 2007;142(6):554-559; discussion 559-560.
10.
ObergSJohanssonJWennerJ, et al. Endoscopic surveillance of columnar-lined esophagus: frequency of intestinal metaplasia detection and impact of antireflux surgery. Ann Surg. 2001;234(5):619-626.
11.
WetscherGJGadenstaetterMKlinglerPJ, et al. Efficacy of medical therapy and antireflux surgery to prevent Barrett’s metaplasia in patients with gastroesophageal reflux disease. Ann Surg. 2001;234(5):627-632.
12.
LabenzJNoconMLindT, et al. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease. Am J Gastroenterol. 2006;101(11):2457-2462.
13.
DeMeesterSRDeMeesterTR. Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy. Ann Surg. 2000;231(3):303-321.
14.
ChangEYMorrisCDSeltmanAK, et al. The effect of antireflux surgery on esophageal carcinogenesis in patients with barrett esophagus: a systematic review. Ann Surg. 2007;246(1):11-21.
15.
MorrowEBushyheadDWassenaarE, et al. The impact of laparoscopic anti-reflux surgery in patients with Barrett’s esophagus. Surg Endosc. 2014;28(12):3279-3284.
16.
DeMeesterSRCamposGMDeMeesterTR, et al. The impact of an antireflux procedure on intestinal metaplasia of the cardia. Ann Surg. 1998;228(4):547-556.
17.
LowDELevineDSDailDHKozarekRA, et al. Histological and anatomic changes in Barrett’s esophagus after antireflux surgery. Am J Gastroenterol. 1999;94(1):80-85.
18.
OelschlagerBKBarrecaMChangLOleynikovDPellegriniCA. Clinical and pathologic response of Barrett’s esophagus to laparoscopic antireflux surgery. Ann Surg. 2003;238(4):458-464; discussion 464-466.
19.
CsendesABraghettoIBurdilesPSmokGHenríquezABurgosAM. Late results of the surgical treatment of 125 patients with short-segment Barrett esophagus. Arch Surg. 2009;144(10):921-927.
20.
AlicubenETTatumJMBildzukewiczN, et al. Regression of intestinal metaplasia following magnetic sphincter augmentation device placement. Surg Endosc. 2019;33:576-579.
21.
SolanskyDKrishnamoorthiRCrewsN, et al. Barrett esophagus length, nodularity, and low-grade dysplasia are predictive of progression to esophageal adenocarcinoma. J Clin Gastroenterol. 2019;53:361-365.
22.
McDonaldMLTrastekVFAllenMSDeschampsCPairoleroPCPairoleroPC, et al. Barretts’s esophagus: does an antireflux procedure reduce the need for endoscopic surveillance?. J Thorac Cardiovasc Surg. 1996;111(6):1135-1138; discussion 1139-1140.
23.
ObergSWennerJJohanssonJWaltherBWillénR. Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg. 2005;242(1):49-54.
24.
ParrillaPMartínezdeHaroLFOrtizA, et al. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett’s esophagus. Ann Surg. 2003;237(3):291-298.
25.
Martinez de HaroLFOrtizAParrillaP, et al. Long-term follow-up of malignancy biomarkers in patients with Barrett’s esophagus undergoing medical or surgical treatment. Ann Surg. 2012;255(5):916-921.
26.
LagergrenJYeWLagergrenPLuY. The risk of esophageal adenocarcinoma after antireflux surgery. Gastroenterology. 2010;138(4):1297-1301.
27.
DeMeesterSR. Antireflux surgery and the risk of esophageal adenocarcinoma: an antithetical view of the data from sweden. Ann Surg. 2013;257(4):583-585.
28.
LagergrenJViklundP. Is esophageal adenocarcinoma occurring late after antireflux surgery due to persistent postoperative reflux?World J Surg. 2007; 31(3):465-469.
29.
LofdahlHELuYLagergrenPLagergrenJ. Risk factors for esophageal adenocarcinoma after antireflux surgery. Ann Surg. 2013;257:579-582.
30.
Maret-OudaJKoningsPLagergrenJBrusselaersN. Antireflux surgery and risk of esophageal adenocarcinoma: a systematic review and meta-analysis. Ann Surg. 2016; 263(2):251-257.
31.
ObergSDeMeesterTRPetersJH, et al. The extent of Barrett’s esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure. J Thorac Cardiovasc Surg. 1999;117(3):572-580.
